Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.
Clin Microbiol Infect. 2022 Jun;28(6):871-878. doi: 10.1016/j.cmi.2022.01.033. Epub 2022 Feb 25.
We estimated the length of stay (LoS) in hospital and the intensive care unit (ICU) and risk of admission to ICU and in-hospital death among COVID-19 patients ≥18 years in Norway who had been fully vaccinated with an mRNA vaccine (at least two doses or one dose and previous SARS-CoV-2 infection), compared to unvaccinated patients.
Using national registry data, we analyzed SARS-CoV-2-positive patients hospitalized in Norway between 1 February and 30 November 2021, with COVID-19 as the main cause of hospitalization. We ran Cox proportional hazards models adjusting for vaccination status, age, sex, county of residence, regional health authority, date of admission, country of birth, virus variant, and underlying risk factors.
We included 716 fully vaccinated patients (crude overall median LoS: 5.2 days; admitted to ICU: 103 (14%); in-hospital death: 86 (13%)) and 2487 unvaccinated patients (crude overall median LoS: 5.0 days; admitted to ICU: 480 (19%); in-hospital death: 102 (4%)). In adjusted models, fully vaccinated patients had a shorter overall LoS in hospital (adjusted log hazard ratios (aHR) for discharge: 1.61, 95% CI: 1.24-2.08), shorter LoS without ICU (aHR: 1.27, 95% CI: 1.07-1.52), and lower risk of ICU admission (aHR: 0.50, 95% CI: 0.37-0.69) compared to unvaccinated patients. We observed no difference in the LoS in ICU or in risk of in-hospital death between fully vaccinated and unvaccinated patients.
Fully vaccinated patients hospitalized with COVID-19 in Norway have a shorter LoS and lower risk of ICU admission than unvaccinated patients. These findings can support patient management and ongoing capacity planning in hospitals.
我们评估了在挪威，与未接种疫苗的患者相比，完全接种了 mRNA 疫苗（至少两剂或一剂和先前的 SARS-CoV-2 感染）的 COVID-19 患者≥18 岁，其住院时间（LoS）和 ICU 入住率以及 ICU 入住和院内死亡风险。
使用全国登记数据，我们分析了 2021 年 2 月 1 日至 11 月 30 日期间在挪威住院的 SARS-CoV-2 阳性患者，将 COVID-19 作为住院的主要原因。我们使用 Cox 比例风险模型，根据疫苗接种状况、年龄、性别、居住地、地区卫生局、入院日期、出生地、病毒变体和潜在危险因素进行调整。
我们纳入了 716 名完全接种疫苗的患者（总粗中位 LOS：5.2 天；入住 ICU：103 例（14%）；院内死亡：86 例（13%））和 2487 名未接种疫苗的患者（总粗中位 LOS：5.0 天；入住 ICU：480 例（19%）；院内死亡：102 例（4%））。在调整后的模型中，与未接种疫苗的患者相比，完全接种疫苗的患者住院总体 LOS 更短（出院调整后的对数风险比（aHR）：1.61，95%CI：1.24-2.08），无 ICU 的 LOS 更短（aHR：1.27，95%CI：1.07-1.52），且 ICU 入住风险更低（aHR：0.50，95%CI：0.37-0.69）。我们未观察到完全接种疫苗的患者与未接种疫苗的患者在 ICU 中的 LOS 或院内死亡风险方面存在差异。
在挪威，因 COVID-19 住院的完全接种疫苗的患者与未接种疫苗的患者相比，其住院时间更短，ICU 入住风险更低。这些发现可以支持患者管理和医院持续的容量规划。
